top of page


Onco-Summaries: Daily Oncology Updates at a Glance
09/10/2025 Adcendo's ADCE-D01 received the FDA fast track designation for the treatment of STS ( Ref ) The US FDA granted the fast track...
Oncofocus Team
Oct 10, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
08/10/2025 Regeneron's cemiplimab has been approved by the US FDA for the adjuvant Tx of CSCC ( Ref ) The US FDA approved Regeneron...
Oncofocus Team
Oct 9, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
07/10/2025 Precision NeuroMed's cinetredekin besudotox received the FDA orphan drug designation for GBM ( Ref ) The US FDA granted the...
Oncofocus Team
Oct 8, 20251 min read


Oncology Updates - Key Oncology News
October 1st Week, 2025 Regulatory Events 🎯 The US FDA approved Jazz Pharmaceuticals ' lurbinectedin (DNA alkylating agent) + Roche 's...
Oncofocus Team
Oct 7, 20252 min read


Oncology Updates - Key Oncology News
September 4th Week, 2025 Regulatory Events 🎯 The US FDA approved Eli Lilly and Company 's imlunestrant (oral estrogen receptor...
Oncofocus Team
Oct 3, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
02/10/2025 Aminex Therapeutics' AMXT 1501 + DFMO received the FDA Orphan Drug Designation for Neuroblastoma ( Ref ) The US FDA granted...
Oncofocus Team
Oct 3, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
30/09/2025 Umoja Biopharma's UB-VV111 in vivo CAR T cell therapy received the FDA fast track designation for B-Cell Malignancies ( Ref )...
Oncofocus Team
Oct 3, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
29/09/2025 In an ~$8B deal, Genmab will acquire Merus in an all-cash transaction ( Ref ) Genmab and Merus announced a transaction...
Oncofocus Team
Sep 29, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
25/09/2025 Eli Lilly and Company's Inluriyo has been approved in the US for ER+, HER2–, ESR1-mutated breast cancer ( Ref ) The US FDA...
Oncofocus Team
Sep 26, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
22/09/2025 Nuvalent completed the NDA submission to the FDA for zidesamtinib in ROS +ve NSCLC ( Ref ) Nuvalent, Inc has completed its NDA...
Oncofocus Team
Sep 24, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
19/09/2025 Merck & Co/MSD received positive EU CHMP Opinions for perioperative pembrolizumab regimen in SCCHN, and for subcutaneous...
Oncofocus Team
Sep 24, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
12/09/2025 The NDA for Alphamab Oncology and CSPC Pharma's anbenitamab + chemo has been accepted by the NMPA for HER2 +ve GC/GEJC ( Ref )...
Oncofocus Team
Sep 15, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
11/09/2025 Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan has been accepted for review in the EU for HER2 +ve solid tumors ( Ref...
Oncofocus Team
Sep 12, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
10/09/2025 Greenwich LifeSciences' GLSI-100 received the FDA fast track designation for HER2+ve breast cancer ( Ref ) The US FDA granted...
Oncofocus Team
Sep 11, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
09/09/2025 Johnson & Johnson's INLEXZO received US FDA approval for NMIBC ( Ref ) The US FDA approved Johnson & Johnson's INLEXZO™...
Oncofocus Team
Sep 10, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
08/09/2025 Beyond Air's BA-101 received the Orphan Drug Designation for GBM ( Ref ) The US FDA granted the Orphan Drug Designation to...
Oncofocus Team
Sep 9, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
05/09/2025 CERo Therapeutics' CER-1236 received the FDA Fast Track Designation for AML ( Ref ) The US FDA granted the Fast Track...
Oncofocus Team
Sep 8, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
04/09/2025 Eli Lilly and Company's olomorasib in combination with Keytruda received the FDA Breakthrough Therapy designation...
Oncofocus Team
Sep 5, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
03/09/2025 Boehringer Ingelheim's zongertinib received the FDA Breakthrough Therapy Designation for first-line HER2-mutant advanced NSCLC...
Oncofocus Team
Sep 4, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
01/09/2025 Boehringer’s zongertinib received accelerated approval in China for HER2-mutant advanced NSCLC ( Ref ) China’s National...
Oncofocus Team
Sep 2, 20251 min read
bottom of page
.png)